I would never profess that I know all the secrets of why cancer cells are so hard to kill off. But, I do know that these cells are tactfully adaptive, extremely resilient and highly versatile, so that they can escape many of current treatment efforts. It seems so hopeless. Although in this era of cancer immunotherapy, better cancer controls are achieved without significant pain, response rates are disappointingly low. Now, the tumor microenvironment adjacent to cancers have been found to be the devil’s haven: the “headquarters” housing the very well protected “queen bee” who most efficiently orchestrate with due confidence the battle between the host immunity and cancer cells. Although strategically, the “headquarters” together with the “queen bee” must be destroyed completely, such efforts still have considerable disappointments, e.g., the recent failure to control the IDO enzyme as possibly one of the main “queen bees” have failed. It’s the numerous “plan Bs” and “plan C” that readily allow the devil to evade any direct confrontation. That’s why we still lose out. On the other hand, there’s a ray of hope as one begins to suspect that the “umbrella coverage” strategy of tackling the evasive “queen bees” of nasty cancer cells might be much more prudent. Of course, it’s very much easier said than done and that’s why we initially attempt to summarize our current thoughts in our evidence-based but readable book just published this month, “Bridging the Gap: In This Era of Cancer Immunotherapy”. We’re also very fortunate to have attracted some favorable peer remarks; please visit the website:

https://novapublishers.com/shop/bridging-the-gap-in-this-era-of-cancer-immunotherapy/